Baseline SUVmax of 18F-FDG PET-CT indicates prognosis of extranodal natural killer/T-cell lymphoma

Xia, Xianwu; Wang, Yaqi; Yuan, Jianjun; Sun, Wenjie; Jiang, Jinjin; Liu, Chang; Zhang, Qunling; Ma, Xiaofen

doi:10.1097/md.0000000000022143

Cited by 8 publications

(10 citation statements)

References 30 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…However, the initial PET SUVmax was ≤7, and univariate analysis showed that this factor had a favorable impact on CR acquisition. This was consistent with the findings of other studies that poor prognostic factors were present when the initial PET SUVmax was high 18,19 . Patients with relapsed or refractory mantle cell lymphoma or follicular lymphoma have various treatment options.…”

Section: Discussionsupporting

confidence: 91%

“…This was consistent with the findings of other studies that poor prognostic factors were present when the initial PET SUVmax was high. 18,19 Patients with relapsed or refractory mantle cell lymphoma or follicular lymphoma have various treatment options. These results suggest that RIT treatment can be an effective treatment option for some patients with low PET SUVmax and difficult autologous stem cell transplantation because of their old age or comorbidities.…”

Section: Discussionmentioning

confidence: 99%

See 1 more Smart Citation

Radioimmunotherapy with ¹³¹I‐rituximab for patients with relapsed or refractory follicular or mantle cell lymphoma

Jang

Lim

Lee

et al. 2023

Asia-Pac J Clncl Oncology

View full text Add to dashboard Cite

AimThis study aimed to evaluate the safety and efficacy of 131I‐rituximab in patients with relapsed or refractory follicular or mantle cell lymphoma.MethodsTwenty‐four patients with relapsed or refractory follicular or mantle cell lymphoma were administered unlabeled rituximab (70 mg) immediately before receiving a therapeutic dose of 131I‐rituximab. Contrast‐enhanced 18F‐fluorodeoxyglucose positron emission tomography/computed tomography was used a month later to assess tumor response.ResultsThis study enrolled 24 patients between June 2012 and 2022. Depending on how they responded to radioimmunotherapy (RIT), 131I‐rituximab was administered one to five times. Of the 24 patients, 9 achieved complete response after RIT and 8 achieved partial response. The median progression‐free and overall survival was 5.9 and 37.9 months, respectively. During the follow‐up period of 64.2 months, three patients were diagnosed with a secondary malignancy. Among treatment‐related adverse events, hematologic toxicities were common, and grade 3–4 thrombocytopenia and neutropenia were reported in 66.6% of cases.Conclusion131I‐rituximab has an effective and favorable safety profile in patients with relapsed or refractory follicular lymphoma and mantle cell lymphoma. This suggests that RIT may also be considered a treatment option for patients with relapsed or refractory follicular lymphoma and mantle cell lymphoma.

show abstract

Section: Discussionsupporting

confidence: 91%

Section: Discussionmentioning

confidence: 99%

Radioimmunotherapy with ¹³¹I‐rituximab for patients with relapsed or refractory follicular or mantle cell lymphoma

Jang

Lim

Lee

et al. 2023

Asia-Pac J Clncl Oncology

View full text Add to dashboard Cite

show abstract

“…The elevated FDG uptake of spleen is reported to be resulted from the activation of T cells and macrophages stimulated by IFN-γ (38). In other disease, Xia et al retrospectively analyzed 141 patients with extranodal NK/T lymphoma and found that SUVmax-lesions ≥ 9.65 was associated with poor prognosis (39).…”

Section: Discussionmentioning

confidence: 99%

The Role of Pre-therapeutic 18F-FDG PET/CT in Pediatric Hemophagocytic Lymphohistiocytosis With Epstein-Barr Virus Infection

Wei

Yang

et al. 2022

Front. Med.

View full text Add to dashboard Cite

ObjectiveTo evaluate the role of pre-therapeutic 18F-FDG PET/CT in pediatric hemophagocytic lymphohistiocytosis (HLH) with Epstein-Barr virus (EBV) infection.MethodsThis retrospective study included 29 HLH children (1–16 years) with EBV infection, who underwent pre-therapeutic 18F-FDG PET/CT from July 2018 to November 2020. Pathology results were considered as the reference standard. These patients were divided into two groups: EBV-induced malignancy-associated HLH (M-HLH, N = 9) and EBV-induced non-malignancy-associated HLH (NM-HLH, N = 20). The regions of interest (ROIs) of the liver, spleen (Sp), bone marrow (BM), lymph nodes (LN), hypermetabolic lesions, liver background (LiBG), and mediastinum (M) were drawn with software 3D-Slicer. The volumetric and metabolic parameters, including maximum standard uptake value (SUVmax), metabolic tumor volume, and total lesion glycolysis of these ROIs, clinical parameters, and laboratory parameters were compared between the two groups. The efficiency of the above parameters in predicting the treatment response and overall survival (OS) was analyzed.ResultsReceiver operating characteristic curve analysis indicated that SUVmax-lesions and SUVmax-LN/M (AUC = 0.822, 0.819, cut-off = 6.04, 5.74, respectively) performed better in differentiating M-HLH from NM-HLH. It had the best diagnostic performance when age was added with the SUVmax-LN/M (AUC = 0.933, sensitivity = 100%, specificity = 85.0%). The presence of extranodal hypermetabolic lesions in multiple organs indicated the M-HLH (P = 0.022). Older age, higher SUVmax-LN and SUVmax-lesions, and the presence of serous effusion were associated with poorer treatment response at the 2nd and 4th week (not reaching partial remission). Multivariate analysis showed that SUVmax-lesions > 7.66 and SUVmax-Sp/LiBG > 2.01 were independent prognostic factors for overall survival (P = 0.025, 0.036, respectively).Conclusions18F-FDG PET/CT could be a valuable technique for identifying the underlying malignancy and predicting prognosis in pediatric HLH with EBV infection. M-HLH could be considered when SUVmax-lesions > 6.04, SUVmax-LN/M > 5.74, and the presence of extranodal hypermetabolic lesions in multiple organs on 18F-FDG PET/CT. SUVmax-lesions and SUVmax-Sp/LiBG might be independent prognostic factors for OS.

show abstract

“…18 F-Fluorodeoxyglucose positron emission tomography/computed tomography ( 18 F-FDG PET/CT) is widely used for the diagnosis of neoplastic diseases. It helps differentiate between benign and malignant lesions, determine the stage of cancers, and plan treatment methods [ 1 , 2 , 3 , 4 , 5 , 6 ]. It is used to diagnose ischemic, inflammatory, and degenerative diseases [ 7 , 8 , 9 , 10 , 11 , 12 ].…”

Section: Introductionmentioning

confidence: 99%

Enhancement of 18F-Fluorodeoxyglucose PET Image Quality by Deep-Learning-Based Image Reconstruction Using Advanced Intelligent Clear-IQ Engine in Semiconductor-Based PET/CT Scanners

et al. 2022

View full text Add to dashboard Cite

Deep learning (DL) image quality improvement has been studied for application to 18F-fluorodeoxyglucose positron emission tomography/computed tomography (18F-FDG PET/CT). It is unclear, however, whether DL can increase the quality of images obtained with semiconductor-based PET/CT scanners. This study aimed to compare the quality of semiconductor-based PET/CT scanner images obtained by DL-based technology and conventional OSEM image with Gaussian postfilter. For DL-based data processing implementation, we used Advanced Intelligent Clear-IQ Engine (AiCE, Canon Medical Systems, Tochigi, Japan) and for OSEM images, Gaussian postfilter of 3 mm FWHM is used. Thirty patients who underwent semiconductor-based PET/CT scanner imaging between May 6, 2021, and May 19, 2021, were enrolled. We compared AiCE images and OSEM images and scored them for delineation, image noise, and overall image quality. We also measured standardized uptake values (SUVs) in tumors and healthy tissues and compared them between AiCE and OSEM. AiCE images scored significantly higher than OSEM images for delineation, image noise, and overall image quality. The Fleiss kappa value for the interobserver agreement was 0.57. Among the 21 SUV measurements in healthy organs, 11 (52.4%) measurements were significantly different between AiCE and OSEM images. More pathological lesions were detected in AiCE images as compared with OSEM images, with AiCE images showing higher SUVs for pathological lesions than OSEM images. AiCE can improve the quality of images acquired with semiconductor-based PET/CT scanners, including the noise level, contrast, and tumor detection capability.

show abstract

Baseline SUVmax of 18F-FDG PET-CT indicates prognosis of extranodal natural killer/T-cell lymphoma

Abstract: Supplemental Digital Content is available in the text

Cited by 8 publications

References 30 publications

Radioimmunotherapy with ¹³¹I‐rituximab for patients with relapsed or refractory follicular or mantle cell lymphoma

Radioimmunotherapy with ¹³¹I‐rituximab for patients with relapsed or refractory follicular or mantle cell lymphoma

The Role of Pre-therapeutic 18F-FDG PET/CT in Pediatric Hemophagocytic Lymphohistiocytosis With Epstein-Barr Virus Infection

Enhancement of 18F-Fluorodeoxyglucose PET Image Quality by Deep-Learning-Based Image Reconstruction Using Advanced Intelligent Clear-IQ Engine in Semiconductor-Based PET/CT Scanners

Contact Info

Product

Resources

About

Baseline SUVmax of 18F-FDG PET-CT indicates prognosis of extranodal natural killer/T-cell lymphoma

Abstract: Supplemental Digital Content is available in the text

Cited by 8 publications

References 30 publications

Radioimmunotherapy with 131I‐rituximab for patients with relapsed or refractory follicular or mantle cell lymphoma

Radioimmunotherapy with 131I‐rituximab for patients with relapsed or refractory follicular or mantle cell lymphoma

The Role of Pre-therapeutic 18F-FDG PET/CT in Pediatric Hemophagocytic Lymphohistiocytosis With Epstein-Barr Virus Infection

Enhancement of 18F-Fluorodeoxyglucose PET Image Quality by Deep-Learning-Based Image Reconstruction Using Advanced Intelligent Clear-IQ Engine in Semiconductor-Based PET/CT Scanners

Contact Info

Product

Resources

About

Radioimmunotherapy with ¹³¹I‐rituximab for patients with relapsed or refractory follicular or mantle cell lymphoma

Radioimmunotherapy with ¹³¹I‐rituximab for patients with relapsed or refractory follicular or mantle cell lymphoma